Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.42 |
| ▸ | PLA2G2D | Q9UNK4 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | RORC | P51449 | 1/20 | 0.41 |
| ▸ | MRGPRX4 | Q96LA9 | 4/20 | 0.40 |
| ▸ | TTR | P02766 | 2/20 | 0.39 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.38 |
| ▸ | CACNG8 | Q8WXS5 | 1/20 | 0.38 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7908665 | 0.87 | PLA2G2D (0.49) | PLA2G2DTTRTRPV1PTPN1KDM4E | |
| SCHEMBL16509549 | 0.86 | TP53 (0.41) | MRGPRX4MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL16503571 | 0.85 | MCL1 (0.35) | SLC22A12PPARGRORCGRIA1CACNG8 | |
| SCHEMBL7920119 | 0.85 | PLA2G2D (0.44) | SLC22A12PLA2G2DPPARGRORCMRGPRX4 | |
| SCHEMBL7923274 | 0.84 | HTR2B (0.47) | — | |
| SCHEMBL10064300 | 0.84 | KDM4E (0.41) | SLC22A12MRGPRX4TTRKDM4EMEN1 | |
| SCHEMBL16502465 | 0.83 | SLC22A12 (0.46) | SLC22A12PLA2G2DTTRPTPN1 | |
| SCHEMBL16503469 | 0.82 | MRGPRX4 (0.47) | SLC22A12PLA2G2DMRGPRX4TTRTRPV1 | |
| SCHEMBL16502478 | 0.82 | ALDH1A1 (0.41) | SLC22A12KDM4EMEN1ALDH1A1MAPT | |
| SCHEMBL7918238 | 0.82 | TTR (0.48) | PLA2G2DTTRTRPV1PTPN1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110306621-A1 | ACYLGUANIDINE DERIVATIVES | ASTELLAS PHARMA INC. (JP) | 2011-12-15 | — | — | US | disclosed |
| WO-2010090304-A1 | ACYLGUANIDINE DERIVATIVE | アステラス製薬株式会社 (JP) | 2010-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110306621-A1 | ACYLGUANIDINE DERIVATIVES | HTR5A, HTR2A, HTR1A | SLC22A12 1344/4885PLA2G2D 841/4885PPARG 589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.